Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Amy Schumer shared she quit Wegovy due to side effects like nausea but was "having a really good experience" with Mounjaro, ...

By Puyaan Singh (Reuters) - The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a ...

The drugmaker accuses Premier Weight Loss of risking patients' health by selling altered, unsterile versions of its ...

Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

Also in this newsletter, the weight-loss drug Mounjaro makes its India debut and stock markets on ‘liberation day’ ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.